Mast cells as regulators of skin inflammation and immunity

Acta Dermato-Venereologica

Volumn 91, Issue 6, 2011, Pages 1-10

  Harvima, Ilkka T ^a   Nilsson, Gunnar ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Immunosuppression; Inflammation; Mast cell; Mediator; Skin

Indexed keywords

5' NUCLEOTIDASE; CD30 LIGAND; CD39 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHYMASE; CYTOKINE; GROWTH FACTOR; HISTAMINE; ILAPRAZOLE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LIGAND; LIPID; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NERVE GROWTH FACTOR; OX40 LIGAND; SERINE PROTEINASE; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; TRYPTASE; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANAPHYLAXIS; CELL ACTIVATION; CYTOKINE RELEASE; DEGRANULATION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; MAST CELL; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 80054962163     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1197     Document Type: Review

References (149)

1. Harvima IT, Nilsson G, Suttle M-M, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res 2008; 300: 461-478.
2. Maurer M, Lopez Kostka S, Siebenhaar F, Moelle K, Metz M, Knop J, et al. Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J 2006; 20: 2460-2467.
3. Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, et al. Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol 2007; 170: 1910-1916.
4. Metz M, Mageri M, Kühl NF, Valeva A, Bhakdi S, Maurer M. Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Exp Dermatol 2008; 18: 160-166.
5. Metz M, Piliponsky AM, Chen C-C, Lammel V, Abrink M, Pejler G, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006; 313: 526-530.
6. Huttunen M, Aalto M-L, Harvima RJ, Horsmanheimo M, Harvima IT. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds. Exp Dermatol 2000; 9: 258-265.
7. Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. FASEB J 2006; 20: 2366-2368.
8. Irani A-MA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 37: 1509-1515.
9. Schechter NM, Irani A-MA, Sprows JL, Abernethy J, Wintroub B, Schwartz LB. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. J Immunol 1990; 145: 2652-2661.
10. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites: fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Path Res Pract 1993; 189: 156-162.
11. Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB. Fc?RIIa, not Fc?RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol 2006; 177: 694-701.
12. Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD. Activation of human mast cells through the high affinity IgG receptor. Mol Immunol 2001; 38: 1289-1293.
13. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol 2007; 19: 31-38.
14. el-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994; 102: 803-806.
15. Church MK, Lowman MA, Rees PH, Benyon RC. Mast cells, neuropeptides and inflammation. Agents Actions 1989; 27: 8-16.
16. Dvorak AM, Costa JJ, Monahan-Earley RA, Fox P, Galli SJ. Ultrastructural analysis of human skin biopsy specimens from patients receiving recombinant human stem cell factor: subcutaneous injection of rhSCF induces mast cell degranulation and granulocyte recruitment at the injection site. J Allergy Clin Immunol 1998; 101: 793-806.
17. van Overveld FJ, Jorens PG, Rampart M, de Backer W, Vermeire PA. Tumour necrosis factor stimulates human skin mast cells to release of histamine and tryptase. Clin Exp Allergy 1991; 21: 711-714.
18. Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006; 126: 746-755.
19. Schiemann F, Brandt E, Gross R, Lindner B, Mittelstädt J, Sommerhoff CP, et al. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J Immunol 2009; 183: 2223-2231.
20. Grützkau A, Henz BM, Kirchhof L, Luger T, Artuc M. alpha;-Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. Biochem Biophys Res Commun 2000; 278: 14-19.
21. Cao J, Cetrulo CL, Theoharides TC. Corticotropinreleasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 2006; 69: 998-1006.
22. Fischer M, Harvima IT, Carvalho RFS, Möller C, Naukkarinen A, Enblad G, et al. Mast cell CD30 ligand is up-regulated in cutaneous inflammations and mediates degranulation-independent chemokine secretion. J Clin Invest 2006; 116: 2748-2756.
23. Dvorak AM, Kissell S. Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. J Leukoc Biol 1991; 49: 197-210.
24. Skokos D, Goubran Botros H, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170: 3037-3045.
25. Krogstad AL, Lönnroth P, Larson G, Wallin BG. Increased interstitial histamine concentration in the psoriatic plaque. J Invest Dermatol 1997; 109: 632-635.
26. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Derm Venereol 1998; 78: 190-193.
27. Juremalm M, Nilsson G. Chemokine receptor expression by mast cells. Chem Immunol Allergy 2005; 87; 130-144.
28. Sayed BA, Brown MA. Mast cells as modulators of T-cell responses. Immunol Rev 2007; 217: 53-64.
29. Harvima IT, Naukkarinen A, Harvima RJ, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res 1989; 281: 387-391.
30. Harvima IT, Naukkarinen A, Paukkonen K, Harvima RJ, Aalto M-L, Schwartz LB, et al. Mast cell tryptase and chymase in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285: 184-192.
31. Diaconu N-C, Kaminska R, Naukkarinen A, Harvima RJ, Harvima IT. The increase in tryptase- and chymasepositive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. J Eur Acad Dermatol Venereol 2007; 21: 908-915.
32. Huttunen M, Harvima IT. Mast cell tryptase and chymase in chronic leg ulcers: chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors. Br J Dermatol 2005; 152: 1149-1160.
33. Green RM, Cordero A, Winkelmann RK. Epidermal mast cells. Arch Dermatol 1977; 113: 166-169.
34. Bolton LL, Montagna W. Mast cells in human ulcers. Am J Dermatopathol 1993; 15: 133-138.
35. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, et al. Effects of T-helper 2-type cytokines, interleukins-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995; 86: 3705-3714.
36. Nilsson G, Blom T, Harvima I, Kusche-Gullberg M, Nilsson K. Stem cell factor-dependent human cord blood derived mast cells express a- and ß-tryptase, heparin and chondroitin sulphate. Immunology 1996; 88: 308-314.
37. Möller C, Alfredsson J, Engström M, Wootz H, Xiang Z, Lennartsson J, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005; 106: 1330-1336.
38. Frenz AM, Gibbs BF, Pearce FL. The effect of recombinant stem cell factor on human skin and lung mast cells and basophil leukocytes. Inflamm Res 1997; 46: 35-39.
39. Kambe N, Kambe M, Kochan JP, Schwartz LB. Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood 2001; 97: 2045-2052.
40. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, et al Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183: 2681-2686.
41. Waskow C, Bartels S, Schlenner SM, Costa C, Rodewald H-R. Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin. Blood 2007; 109: 5363-5370.
42. Huttunen M, Naukkarinen A, Horsmanheimo M, Harvima IT. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing. Arch Dermatol Res 2002; 294: 324-330.
43. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in basal cell carcinoma. Br J Dermatol 1997; 137: 709-713.
44. Yamamoto T, Katayama I, Nishioka K. Possible contribution of stem cell factor in psoriasis vulgaris. J Dermatol Sci 2000; 24: 171-176.
45. Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, et al. Human mast cells express stem cell factor. J Pathol 1998; 186: 59-66.
46. Hjertson M, Kivinen PK, Dimberg L, Nilsson K, Harvima IT, Nilsson G. Retinoic acid inhibits in vitro development of mast cells but has no marked effect on mature human skin tryptase- and chymase-positive mast cells. J Invest Dermatol 2003; 120: 239-245.
47. Xiang Z, Ahmed AA, Möller C, Nakayama K, Hatakeyama S, Nilsson G. Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med 2001; 194: 1561-1569.
48. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 1994; 153: 3717-3723.
49. Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G. The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1a acts as a mast cell chemotaxin. Eur J Immunol 2000; 30: 3614-3622.
50. Olsson N, Piek E, ten Dijke P, Nilsson G. Human mast cell migration in response to members of the transforming growth factor-ß family. J Leukoc Biol 2000; 67: 350-356.
51. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003; 170: 3461-3467.
52. Sawai N, Koike K, Mwamtemi HH, Kinoshita T, Kurokawa Y, Sakashita K, et al. Thrombopoietin augments stem cell factor-dependent growth of human mast cells from bonemarrow multipotential hematopoietic progenitors. Blood 1999; 93: 3703-3712.
53. Kanbe N, Kurosawa M, Miyachi Y, Kanbe M, Saitoh H, Matsuda H. Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells synergis- tically with stem cell factor. Clin Exp Allergy 2000; 30: 1113-1120.
54. Mierke CT, Ballmaier M, Werner U, Manns MP, Welte K, Bischoff SC. Human endothelial cells regulate survival and proliferation of human mast cells. J Exp Med 2000; 192: 801-811.
55. Harvima RJ, Harvima IT, Dull D, Dunder UK, Schwartz LB. Identification and characterization of multiple forms of tryptase from human mast cells. Arch Dermatol Res 1999; 291: 73-80.
56. Pereira PJB, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, et al. Human ß-tryptase is a ringlike tetramer with active sites facing a central pore. Nature 1998; 392: 306-311.
57. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 2001; 40: 7342-7349.
58. Schechter NM, Choi E-J, Selwood T, McCaslin DR. Characterization of three distinct catalytic forms of human tryptase-ß: their interrelationships and relevance. Biochemistry 2007; 46: 9615-9629.
59. Kaminska R, Harvima IT, Naukkarinen A, Nilsson G, Horsmanheimo M. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection. J Pathol 1996; 180: 434-440.
60. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-2700.
61. Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1ß and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol 1998; 161: 1939-1946.
62. Compton SJ, Cairns JA, Holgate ST, Walls AF. Human mast cell tryptase stimulates the release of an IL-8- dependent neutrophil chemotactic activity from human umbilical vein endothelial cells (HUVEC). Clin Exp Immunol 2000; 121: 31-36.
63. Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 1858-1863.
64. Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, et al. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-a, IL-6 and IL-1ß: possible relevance to multiple sclerosis. J Neuroimmunol 2003; 138: 115-122.
65. Wang H, He S. Induction of lactoferrin and IL-8 release from human neutrophils by tryptic enzymes via proteinase activated receptor-2. Cell Biol Int 2006; 30: 688-697.
66. Li T, He S. Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. Immunol Cell Biol 2006; 84: 461-466.
67. He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997; 159: 6216-6225.
68. Carvalho RF, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp Dermatol 2010; 19: 117-122.
69. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23: 6176-6180.
70. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-158.
71. Kaminska R, Helisalmi P, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase. J Invest Dermatol 1999; 113: 567-573.
72. Schechter NM, Brass LF, Lavker RM, Jensen PJ. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. J Cell Physiol 1998; 176: 365-373.
73. Sharlow ER, Paine CS, Babiarz L, Eisinger M, Shapiro S, Seiberg M. The protease-activated receptor-2 upregulates keratinocyte phagocytosis. J Cell Sci 2000; 113: 3093-3101.
74. Buddenkotte J, Stroh C, Engels IH, Moormann C, Shpacovitch VM, Seeliger S, et al. Agonists of proteinaseactivated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol 2005; 124: 38-45.
75. Hou L, Kapas S, Cruchley AT, Macey MG, Harriott P, Chinni C, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology 1998; 94: 356-362.
76. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337-349.
77. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. Synovial procollagenase activation by human mast cell tryptase: dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-1662.
78. Iddamalgoda A, Le QT, Ito K, Tanaka K, Kojima H, Kido H. Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins. Arch Dermatol Res 2008; 300 (suppl 1): S69-S76.
79. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (prourokinase). J Biol Chem 1994; 269: 9416-9419.
80. Fajardo I, Pejler G. Human mast cell ß-tryptase is a gelatinase. J Immunol 2003; 171: 1493-1499.
81. Pang L, Nie M, Corbett L, Sutcliffe A, Knox AJ. Mast cell ß-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities. J Immunol 2006; 176: 3788-3795.
82. Franconi GM, Graf PD, Lazarus SC, Nadel JA, Caughey GH. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the Ferret. J Pharmacol Exp Ther 1989; 248: 947-951.
83. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3: 27-32.
84. Walls AF, Brain SD, Desai A, Jose PJ, Hawkings E, Church MK, et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochem Pharmacol 1992; 43: 1243-1248.
85. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell proteaseproteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immunol 1992; 148: 2475-2482.
86. Whitaker-Menezes D, Schechter NM, Murphy GF. Serine proteinases are regionally segregated within mast cell granules. Lab Invest 1995; 72: 34-41.
87. Kivinen PK, Kaminska R, Naukkarinen A, Harvima RJ, Horsmanheimo M, Harvima IT. Release of soluble tryptase but only minor amounts of chymase activity from cutaneous mast cells. Exp Dermatol 2001; 10: 246-255.
88. Kivinen PK, Nilsson G, Naukkarinen A, Harvima IT. Mast cell survival and apoptosis in organ-cultured human skin. Exp Dermatol 2003; 12: 53-60.
89. Sayama S, Iozzo RV, Lazarus GS, Schechter NM. Human skin chymotrypsin-like proteinase chymase: subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. J Biol Chem 1987; 262: 6808-6815.
90. Walter M, Plotnick M, Schechter NM. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. Arch Biochem Biophys 1996; 327: 81-88.
91. Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989; 264: 21308-21315.
92. Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by a(2)-macroglobulin. Arch Biochem Biophys 1999; 368: 276-284.
93. Schick C, Kamachi Y, Bartuski AJ, Çataltepe S, Schechter NM, Pemberton PA, et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997; 272: 1849-1855.
94. Harvima IT, Haapanen L, Ackermann L, Naukkarinen A, Harvima RJ, Horsmanheimo M. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm Venereol 1999; 79: 98-104.
95. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin. Clin Exp Allergy 2001; 31: 593-601.
96. He S, Walls AF. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol 1998; 125: 1491-1500.
97. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000; 67: 585-589.
98. Terakawa M, Tomimori Y, Goto M, Fukuda Y. Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. Eur J Pharmacol 2006; 538: 175-181.
99. Mizutani H, Schechter NM, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1ß (IL-1ß) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-825.
100. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, et al. Human mast cell chymase cleaves pro- IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006; 177: 8315-8319.
101. Cui P, Tani K, Kitamura H, Okumura Y, Yano M, Inui D, et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol 2001; 70: 306-312.
102. Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J Immunol 2005; 175: 2635-2642.
103. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988; 244: 133-137.
104. Diaconu N-C, Rummukainen J, Naukkarinen A, Mättö M, Harvima RJ, Pelkonen J, et al. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro. Arch Dermatol Res 2011 Jan 29. [Epub ahead of print].
105. Hershko AY, Rivera J. Mast cell and T cell communication: an amplification and control of adaptive immunity. Immunol Lett 2010; 128: 98-104.
106. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 2005; 102: 6467-6472.
107. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006; 176: 2238-2248.
108. Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 2004; 173: 5247-5257.
109. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor a, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 4220-4224.
110. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-a and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 1998; 290: 353-359.
111. Diaconu N-C, Kaminska R, Naukkarinen A, Harvima RJ, Nilsson G, Harvima IT. Increase in CD30 ligand/CD153 and TNF-a expressing mast cells in basal cell carcinoma. Cancer Immunol Imunother 2007; 56: 1407-1415.
112. Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, et al. Mast cells counteract regulatory T cell suppression through interleukin-6 and OX40/OX40L axis toward Th17 cell differentiation. Blood 2009; 114: 2639-2648.
113. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2008; 109: 3640-3648.
114. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441-1452.
115. Horsmanheimo L, Harvima IT, Järvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 1994; 131: 348-353.
116. Ackermann L, Harvima IT, Pelkonen J, Ritamäki-Salo V, Naukkarinen A, Harvima RJ, et al. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 1999; 140: 624-633.
117. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin. Allergy 2001; 56: 58-64. (Erratum: Allergy 2001; 56: 451.)
118. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001; 114: 616-623.
119. Bengtsson Å, Scheynius A, Avila-Cariño J. Crosslinking of CD30 on activated human Th clones enhances their cytokine production and downregulates the CD30 expression. Scand J Immunol 2000; 52: 595-601.
120. Poncet P, Arock M, David B. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. J Leukoc Biol 1999; 66: 105-112.
121. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SM. Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 1998; 66: 6030-6034.
122. Frandji P, Tkaczyk C, Oskeritzian C, David B, Desaymard C, Mécheri S. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Eur J Immunol 1996; 26: 2517-2528.
123. Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, et al. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol 1998; 111: 689-695.
124. Inamura H, Kurosawa M, Kuwasaki T, Kamada Y, Kayaba H, Chihara J. Expression of adhesion molecules on cordblood- derived, cultured human mast cells and effect of dexamethasone on intercellular adhesion molecule-1 expression on the mast cells treated by phorbol myristate acetate. Allergy 2001; 56: 672-678.
125. Brill A, Baram D, Sela U, Salamon P, Mekori YA, Hershkoviz R. Induction of mast cell interactions with blood vessel wall components by direct contact with intact T cells or T cell membranes in vitro. Clin Exp Allergy 2004; 34: 1725-1731.
126. Wang H-W, Tedla N, Lloyd AR, Wakefield D, McNeil HP. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest 1998; 102: 1617-1626.
127. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, Gunn MD, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol 2003; 4: 1199-1205.
128. Jawdat DM, Rowden G, Marshall JS. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol 2006; 177: 1755-1762.
129. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006; 176: 4102-4112.
130. Kitawaki T, Kadowaki N, Sugimoto N, Kambe N, Hori T, Miyachi Y, et al. IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells. Int Immunol 2006; 18: 1789-1799.
131. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003; 112: 15-22.
132. Lu L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002.
133. de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, et al. Mast cell degranulation breaks peripheral tolerance. Am J Transplant 2009; 9: 2270-2280.
134. Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie ANJ, et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 2009; 186: 83-91.
135. Zhang W, Wu K, He W, Gao Y, Huang W, Lin X, et al. Transforming growth factor beta 1 plays an important role in inducing CD4+CD25+forkhead box P3+ regulatory T cells by mast cells. Clin Exp Immunol 2010; 161: 490-496.
136. Forward NA, Furlong SJ, Yang Y, Lin T-J, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol 2009; 183: 3014-3022.
137. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007; 8: 1095-1104.
138. Biggs L, Yu C, Fedoric B, Lopez AF, Galli SJ, Grimbaldeston MA. Evidence that vitamin D3 promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med 2010; 207: 455-463.
139. Byrne SN, Limón-Flores AL, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008; 180: 4648-4655.
140. Limón-Flores AY, Chacón-Salinas R, Ramos G, Ullrich SE. Mast cells mediate the immune suppression induced by dermal exposure to JP-8 jet fuel. Toxicol Sci 2009; 112: 144-152.
141. Depinay N, Hacini F, Beghdadi W, Peronet R, Mécheri S. Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites. J Immunol 2006; 176: 4141-4146.
142. Chacón-Salinas R, Limón-Flores AY, Chávez-Blanco AD, Gonzales-Estrada A, Ullrich SE. Mast cell-derived IL-10 suppresses germinal center formation by affecting T follicular helper cell function. J Immunol 2011; 186: 25-31.
143. Ishizuka T, Okayama Y, Kobayashi H, Mori M. Interleukin-10 is localized to and released by human lung mast cells. Clin Exp Allergy 1999; 29: 1424-1432.
144. Kanbe N, Kurosawa M, Nagata H, Saitoh H, Miyachi Y. Cord blood-derived human cultured mast cells produce transforming growth factor ß1. Clin Exp Allergy 1999; 29: 105-113.
145. Royer B, Varadaradjalou S, Saas P, Gabiot AC, Kantelip B, Féger F, et al. Autocrine regulation of cord blood-derived human mast cell activation by IL-10. J Allergy Clin Immunol 2001; 108: 80-86.
146. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006; 19: 149-159.
147. Huang B, Lei Z, Zhang G-M, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008; 112: 1269-1279.
148. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen G-X, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE 2010; 5: e8922.
149. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 2010; 107: 6430-6435.